US 11,884,718 B2Granted

Potent zika virus-specific and cross-neutralizing monoclonal antibodies to zika and dengue viruses following ZIKV infection or vaccination

AssigneesThe Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Beth Israeli Deaconess Medical Center, Inc., The Government of the United States, as represented by the Secretary of the Army

InventorsShelly Krebs, Gina Donofrio, Vincent Dussupt, Kayvon Modjarrad, Dan Barouch, Richard G. Jarman, III, Nelson L. Michael, Gordon Joyce, Rajeshwer Singh Sankhala, Kathryn Elaine Stephenson

Life of this patent

Estimating the term…

Abstract

The invention described herein provides antibodies to Zika virus. The novel polypeptides are useful alone or as portions of larger molecules, such as antibodies or antibody fragments, that can be used to treat or prevent infection of Zika virus.

Claims17

Dependent claims

An antibody or fragment thereof that selectively binds Zika virus, wherein said antibody comprises:

(a) a heavy chain variable region comprising complementarity determining regions (CDRs) having amino acid sequences SEQ ID NO:
5 for CDR1, SEQ ID NO:
6 for CDR2, and SEQ ID NO:
7 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
8 for CDR1, SEQ ID NO:
9 for CDR2 and SEQ ID NO:
10 for CDR3;
or
(b) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO:
15 for CDR1, SEQ ID NO:
16 for CDR2, and SEQ ID NO:
17 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
18 for CDR1, SEQ ID NO:
19 for CDR2 and SEQ ID NO:
20 for CDR3;
or
(c) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO:
25 for CDR1, SEQ ID NO:
26 for CDR2, and SEQ ID NO:
27 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
28 for CDR1, SEQ ID NO:
29 for CDR2 and SEQ ID NO:
30 for CDR3;
or
(d) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO:
35 for CDR1, SEQ ID NO:
36 for CDR2, and SEQ ID NO:
37 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
38 for CDR1, SEQ ID NO:
39 for CDR2 and SEQ ID NO:
40 for CDR3;
or
(e) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO:
45 for CDR1, SEQ ID NO:
46 for CDR2, and SEQ ID NO:
47 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
48 for CDR1, SEQ ID NO:
49 for CDR2 and SEQ ID NO:
50 for CDR3;
or
(f) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO:
55 for CDR1, SEQ ID NO:
56 for CDR2, and SEQ ID NO:
57 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
58 for CDR1, SEQ ID NO:
59 for CDR2 and SEQ ID NO:
60 for CDR3;
or
(g) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO:
65 for CDR1, SEQ ID NO:
66 for CDR2, and SEQ ID NO:
67 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
68 for CDR1, SEQ ID NO:
69 for CDR2 and SEQ ID NO:
70 for CDR3;
or
(h) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO:
75 for CDR1, SEQ ID NO:
76 for CDR2, and SEQ ID NO:
77 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
78 for CDR1, SEQ ID NO:
79 for CDR2 and SEQ ID NO:
80 for CDR3;
or
(i) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO:
85 for CDR1, SEQ ID NO:
86 for CDR2, and SEQ ID NO:
87 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
88 for CDR1, SEQ ID NO:
89 for CDR2 and SEQ ID NO:
90 for CDR3;
or
(j) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO:
95 for CDR1, SEQ ID NO:
96 for CDR2, and SEQ ID NO:
97 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
98 for CDR1, SEQ ID NO:
99 for CDR2 and SEQ ID NO:
100 for CDR3;
or
(k) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO:
105 for CDR1, SEQ ID NO:
106 for CDR2, and SEQ ID NO:
107 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
108 for CDR1, SEQ ID NO:
109 for CDR2 and SEQ ID NO:
110 for CDR3;
or
(l) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO:
115 for CDR1, SEQ ID NO:
116 for CDR2, and SEQ ID NO:
117 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
118 for CDR1, SEQ ID NO:
119 for CDR2 and SEQ ID NO:
120 for CDR3;
or
(m) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO:
125 for CDR1, SEQ ID NO:
126 for CDR2, and SEQ ID NO:
127 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
128 for CDR1, SEQ ID NO:
129 for CDR2 and SEQ ID NO:
130 for CDR3;
or
(n) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO:
135 for CDR1, SEQ ID NO:
136 for CDR2, and SEQ ID NO:
137 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
138 for CDR1, SEQ ID NO:
139 for CDR2 and SEQ ID NO:
140 for CDR3;
or
(o) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO:
145 for CDR1, SEQ ID NO:
146 for CDR2, and SEQ ID NO:
147 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
148 for CDR1, SEQ ID NO:
149 for CDR2 and SEQ ID NO:
150 for CDR3;
or
(p) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO:
155 for CDR1, SEQ ID NO:
156 for CDR2, and SEQ ID NO:
157 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
158 for CDR1, SEQ ID NO:
159 for CDR2 and SEQ ID NO:
160 for CDR3;
or
(q) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO:
165 for CDR1, SEQ ID NO:
166 for CDR2, and SEQ ID NO:
167 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
168 for CDR1, SEQ ID NO:
169 for CDR2 and SEQ ID NO:
170 for CDR3;
or
(r) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO:
175 for CDR1, SEQ ID NO:
176 for CDR2, and SEQ ID NO:
177 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
178 for CDR1, SEQ ID NO:
179 for CDR2 and SEQ ID NO:
180 for CDR3;
or
(s) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO:
185 for CDR1, SEQ ID NO:
186 for CDR2, and SEQ ID NO:
187 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
188 for CDR1, SEQ ID NO:
189 for CDR2 and SEQ ID NO:
190 for CDR3;
or
(t) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO:
195 for CDR1, SEQ ID NO:
196 for CDR2, and SEQ ID NO:
197 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
198 for CDR1, SEQ ID NO:
199 for CDR2 and SEQ ID NO:
200 for CDR3;
or
(u) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO:
205 for CDR1, SEQ ID NO:
206 for CDR2, and SEQ ID NO:
207 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
208 for CDR1, SEQ ID NO:
209 for CDR2 and SEQ ID NO:
210 for CDR3;
or
(v) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO:
215 for CDR1, SEQ ID NO:
216 for CDR2, and SEQ ID NO:
217 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
218 for CDR1, SEQ ID NO:
219 for CDR2 and SEQ ID NO:
220 for CDR3.

194 more elements

Dependencies are inferred from the claim text.

Facts

Application: 17/049,800Filed 24 Apr 2019 · us provisional application
Priority: 24 Apr 2018
Published: US 2021/0238262 A15 Aug 2021
Granted: 30 Jan 2024
Term ends: Not estimatedThe source records don’t support an estimate.

Classification26 codes

C07K 16/116
RNA viruses: togaviridae ; Matonaviridae ; Flaviviridae
A61K 39/12
Medicinal preparations containing antigens or antibodies: viral antigens
A61P 31/14
Antivirals: for RNA viruses
C12N 7/00
Viruses

Family

Application62/662,211Us provisional application · filed 24 Apr 2018
Application62/697,347Us provisional application · filed 12 Jul 2018
US 2021/0238262 A1Pre-grant publication · published 5 Aug 2021
US 11,884,718 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Potent zika virus-specific and cross-neutralizing monoclonal antibodies to zika and dengue viruses following ZIKV infection or vaccination

InventorsShelly Krebs, Gina Donofrio, Vincent Dussupt, Kayvon Modjarrad, Dan Barouch, Richard G. Jarman, III, Nelson L. Michael, Gordon Joyce, Rajeshwer Singh Sankhala, Kathryn Elaine Stephenson

Life of this patent

Estimating the term…

Abstract

An antibody or fragment thereof that selectively binds Zika virus, wherein said antibody comprises:

(a) a heavy chain variable region comprising complementarity determining regions (CDRs) having amino acid sequences SEQ ID NO:
5 for CDR1, SEQ ID NO:
6 for CDR2, and SEQ ID NO:
7 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
8 for CDR1, SEQ ID NO:
9 for CDR2 and SEQ ID NO:
10 for CDR3;
or
(b) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO:
15 for CDR1, SEQ ID NO:
16 for CDR2, and SEQ ID NO:
17 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
18 for CDR1, SEQ ID NO:
19 for CDR2 and SEQ ID NO:
20 for CDR3;
or
(c) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO:
25 for CDR1, SEQ ID NO:
26 for CDR2, and SEQ ID NO:
27 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
28 for CDR1, SEQ ID NO:
29 for CDR2 and SEQ ID NO:
30 for CDR3;
or
(d) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO:
35 for CDR1, SEQ ID NO:
36 for CDR2, and SEQ ID NO:
37 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
38 for CDR1, SEQ ID NO:
39 for CDR2 and SEQ ID NO:
40 for CDR3;
or
(e) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO:
45 for CDR1, SEQ ID NO:
46 for CDR2, and SEQ ID NO:
47 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
48 for CDR1, SEQ ID NO:
49 for CDR2 and SEQ ID NO:
50 for CDR3;
or
(f) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO:
55 for CDR1, SEQ ID NO:
56 for CDR2, and SEQ ID NO:
57 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
58 for CDR1, SEQ ID NO:
59 for CDR2 and SEQ ID NO:
60 for CDR3;
or
(g) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO:
65 for CDR1, SEQ ID NO:
66 for CDR2, and SEQ ID NO:
67 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
68 for CDR1, SEQ ID NO:
69 for CDR2 and SEQ ID NO:
70 for CDR3;
or
(h) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO:
75 for CDR1, SEQ ID NO:
76 for CDR2, and SEQ ID NO:
77 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
78 for CDR1, SEQ ID NO:
79 for CDR2 and SEQ ID NO:
80 for CDR3;
or
(i) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO:
85 for CDR1, SEQ ID NO:
86 for CDR2, and SEQ ID NO:
87 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
88 for CDR1, SEQ ID NO:
89 for CDR2 and SEQ ID NO:
90 for CDR3;
or
(j) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO:
95 for CDR1, SEQ ID NO:
96 for CDR2, and SEQ ID NO:
97 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
98 for CDR1, SEQ ID NO:
99 for CDR2 and SEQ ID NO:
100 for CDR3;
or
(k) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO:
105 for CDR1, SEQ ID NO:
106 for CDR2, and SEQ ID NO:
107 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
108 for CDR1, SEQ ID NO:
109 for CDR2 and SEQ ID NO:
110 for CDR3;
or
(l) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO:
115 for CDR1, SEQ ID NO:
116 for CDR2, and SEQ ID NO:
117 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
118 for CDR1, SEQ ID NO:
119 for CDR2 and SEQ ID NO:
120 for CDR3;
or
(m) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO:
125 for CDR1, SEQ ID NO:
126 for CDR2, and SEQ ID NO:
127 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
128 for CDR1, SEQ ID NO:
129 for CDR2 and SEQ ID NO:
130 for CDR3;
or
(n) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO:
135 for CDR1, SEQ ID NO:
136 for CDR2, and SEQ ID NO:
137 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
138 for CDR1, SEQ ID NO:
139 for CDR2 and SEQ ID NO:
140 for CDR3;
or
(o) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO:
145 for CDR1, SEQ ID NO:
146 for CDR2, and SEQ ID NO:
147 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
148 for CDR1, SEQ ID NO:
149 for CDR2 and SEQ ID NO:
150 for CDR3;
or
(p) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO:
155 for CDR1, SEQ ID NO:
156 for CDR2, and SEQ ID NO:
157 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
158 for CDR1, SEQ ID NO:
159 for CDR2 and SEQ ID NO:
160 for CDR3;
or
(q) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO:
165 for CDR1, SEQ ID NO:
166 for CDR2, and SEQ ID NO:
167 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
168 for CDR1, SEQ ID NO:
169 for CDR2 and SEQ ID NO:
170 for CDR3;
or
(r) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO:
175 for CDR1, SEQ ID NO:
176 for CDR2, and SEQ ID NO:
177 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
178 for CDR1, SEQ ID NO:
179 for CDR2 and SEQ ID NO:
180 for CDR3;
or
(s) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO:
185 for CDR1, SEQ ID NO:
186 for CDR2, and SEQ ID NO:
187 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
188 for CDR1, SEQ ID NO:
189 for CDR2 and SEQ ID NO:
190 for CDR3;
or
(t) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO:
195 for CDR1, SEQ ID NO:
196 for CDR2, and SEQ ID NO:
197 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
198 for CDR1, SEQ ID NO:
199 for CDR2 and SEQ ID NO:
200 for CDR3;
or
(u) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO:
205 for CDR1, SEQ ID NO:
206 for CDR2, and SEQ ID NO:
207 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
208 for CDR1, SEQ ID NO:
209 for CDR2 and SEQ ID NO:
210 for CDR3;
or
(v) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO:
215 for CDR1, SEQ ID NO:
216 for CDR2, and SEQ ID NO:
217 for CDR3;
and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO:
218 for CDR1, SEQ ID NO:
219 for CDR2 and SEQ ID NO:
220 for CDR3.

194 more elements

Facts

Application

17/049,800Filed 24 Apr 2019 · us provisional application

Priority

24 Apr 2018

Published

US 2021/0238262 A15 Aug 2021

Granted

30 Jan 2024

Term ends

Not estimatedThe source records don’t support an estimate.

Classification26 codes

C07K 16/116
RNA viruses: togaviridae ; Matonaviridae ; Flaviviridae
A61K 39/12
Medicinal preparations containing antigens or antibodies: viral antigens
A61P 31/14
Antivirals: for RNA viruses
C12N 7/00
Viruses